During the past decade, Centro de Investigacion Integral MEDIVEST S.C conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centro de Investigacion Integral MEDIVEST S.C" are "Dermatitis, Atopic" (2 trials), "Dermatitis" (1 trials), "Eczema" (1 trials), "Genetic Diseases, Inborn" (1 trials) and "Hypersensitivity" (1 trials). Many other conditions were trialed in "Centro de Investigacion Integral MEDIVEST S.C" in a lesser frequency.

Most popular intervention types in "Centro de Investigacion Integral MEDIVEST S.C" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "Iclepertin" (1 trials) and "PF-04965842 100 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigacion Integral MEDIVEST S.C" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Centro de Investigacion Integral MEDIVEST S.C". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centro de Investigacion Integral MEDIVEST S.C, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigacion Integral MEDIVEST S.C, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".